Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SORD | Q00796 | 1/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24928805 | 0.79 | SORD (0.35) | HTTMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL12528570 | 0.76 | MEN1 (0.40) | HTTMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL17610997 | 0.75 | PKM (0.38) | MEN1KMT2ANPSR1SMN1; SMN2HPGD | |
| SCHEMBL950324 | 0.74 | HTT (0.36) | HTTMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL21432057 | 0.74 | MEN1 (0.42) | HTTMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL27459320 | 0.74 | MEN1 (0.37) | HTTMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL859854 | 0.74 | MEN1 (0.37) | HTTMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL950572 | 0.74 | HTT (0.36) | HTTMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL950726 | 0.74 | HTT (0.36) | HTTMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL18592843 | 0.73 | HTT (0.35) | HTTMEN1KMT2ANPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3533797-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-20 | — | — | EP | disclosed |
| EP-3533797-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-09-04 | — | — | EP | disclosed |
| EP-2540728-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20170209452-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-07-27 | — | — | US | disclosed |
| US-9655900-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-23 | — | — | US | disclosed |
| US-20160310494-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-10-27 | — | — | US | disclosed |
| US-9388195-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-12 | — | — | US | disclosed |
| US-20150158882-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8933069-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8921354-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20140235615-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-21 | — | — | US | disclosed |
| US-20140228352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| US-8722660-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| EP-2403857-B1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20130029969-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-31 | — | — | US | disclosed |
| EP-2540728-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2403857-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010101302-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | HTT 4327/4885MEN1 1074/4885KMT2A 1565/4885 |
| US-20160310494-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | HTT 1930/4885MEN1 84/4885KMT2A 431/4885 |
| US-20130029969-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | HTT 1930/4885MEN1 84/4885KMT2A 431/4885 |
| US-20150158882-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | HTT 1930/4885MEN1 84/4885KMT2A 431/4885 |
| US-20140228352-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | HTT 1930/4885MEN1 84/4885KMT2A 431/4885 |
| US-20140235615-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | HTT 1930/4885MEN1 84/4885KMT2A 431/4885 |
| US-20170209452-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | HTT 1930/4885MEN1 84/4885KMT2A 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.